realtime dynamix™: hyperkalemia · agent for hyperkalemia to be approved in 50 years. veltassa...
TRANSCRIPT
RealTime Dynamix™: Hyperkalemia
Spherix Global Insights has been following the development of the hyperkalemia market
since June 2015, in advance of the FDA approval of Veltassa (patiromer FOS), the first
agent for hyperkalemia to be approved in 50 years. Veltassa was launched in the US in
January 2016 and is expected to face competition from ZS-9, another novel potassium
binder in development by ZS Pharma (acquired by AstraZeneca in 2015). ZS Pharma was
dealt a blow on April 26, 2016 when, instead of being approved, was issued a Complete
Response Letter. Stay tuned on how this may impact the market.
According to 112
Nephrologists surveyed in
late April 2016, Veltassa
offers promise, efficacy and
innovation, but comes at a
cost
Excited to Try...Four months
post-launch more than half
of the surveyed
nephrologists (left) report
starting patients on
Veltassa, primarily in the
CKD-ND outpatient setting.
Cardiologists report a more
muted response and the
introduction of Veltassa is
less top of mind for this
specialty
RealTime Dynamix: Hyperkalemia is a monthly survey of nephrologists (quarterly survey of cardiologists) focused on tracking
the launch of Veltassa and following the evolution of the hyperkalemia market. For more information contact
Invest in Intelligence That Delivers
Why are some CKD-ND patients with hyperkalemia NOT
candidates for Veltassa?
Allocation of 100 points
6%
9%
15%
16%
20%
24%
8%
According to nephrologists, he black box
warning about DDIs recommending a six hour
dose separation as well as reimbursement
woes are perceived to be disadvantages and
the major barriers to expanded use.
On May 25, 2016 Relypsa filed new data with
the FDA seeking to change the label to reflect
updated drug interaction data and reduce the
six hour recommendation to a three hour
recommendation. Our research suggests that ,
if approved, this will augment use of the
product
Happy with the availability of at least one hyperkalemia
agent, desire for new agents shifts away from ZS-9 to
AbbVie’s atrasentan, in Phase 3 trials for diabetic
nephropathy. (n=112)
After being asked about familiarity with renal pipeline
agents (right), nephrologists were asked which one they
would most like to see approved.